Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Otsuka's Guadecitabine Fails in ASTRAL-1 But AML Studies Continue

Executive Summary

Otsuka's guadecitabine has missed co-primary endpoints in older treatment-naïve AML patients but it continues to be evaluated in relapsed and refractory patients, in a therapeutic area undergoing considerable innovation.

You may also be interested in...



First Approval Globally For Gilteritinib, In Japan For AML

First nod globally for Astellas's FLT3 inhibitor set to further increase competition in AML space, but commercial opportunity in  launch market Japan looks set to be limited.

Tibsovo Approval Makes Agios’ Second AML Approval In A Year; Priced At $26k For 30 Days

Tibsovo is the second targeted therapy approved for a mutation-specific subset of relapsed/refractory AML patients. Agios discovered and jointly markets the first, Idhifa, with Celgene.

Daiichi's Phase III Quizartinib Data Pave Way In Niche AML Market

Showing an overall survival improvement in the especially hard to treat FLT3-ITD mutated patients is a significant achievement in AML, analysts say.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC123518

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel